🚨 FDA Approves capivasertib Plus Abiraterone as First Targeted Therapy for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer Source AstraZeneca buff.ly/ldFb96p The FDA has approved capivasertib in combination with abiraterone and prednisone as the first targeted therapy for patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive #ProstateCancer . Approval was based on the Phase III CAPItello-281 trial, which demonstrated a 19% reduction in the risk of radiographic progression or death and improved median radiographic progression-free survival by 7.5 months. The decision also highlights the growing importance of biomarker-driven treatment and PTEN testing in advanced prostate cancer. @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin #OncoAlertAF @nataliagandur @realbowtiedoc @Onco_Cifu88 @scocmem

JUST IN: @US_FDA approves combo HIF2 inhibitor Belzutifan PD1 inhibitor Pembrolizumab in adjuvant Kidney Cancer. Approval based on LS022 trial co-led with @tompowles1 presented @ASCO #GU26 adding another approval to @NobelPrize story with @kaelin_lab @DanaFarber @DanaFarber_GU ! Onward ! Great day for patients ! #HIF2 #oncology #labubu dailynews.ascopubs.org/do/li… blog.dana-farber.org/insight…

Breaking new👉 today @US_FDA approved capivasertib (oral AKT inhibitor) for the metastatic HSPC/APMS #prostatecancer with PTEN deficiency👉personalized medicine continues to leap forward👉Capitello-281 ph3 trial summary👇 @OncoAlert @urotoday @AUC3_Official

🎯 Felicitaciones por el excelente panel de expertos y las discusiones de alto nivel científico!🙌🙌 👉 este es el camino a seguir del trabajo multidisciplinar centrado en el mejor tratamiento del paciente!! @OncoAlert @InfoAeu @_SEOM @aaoncoclinica @myESMO

Thrilled to share #PRIMARY2 Trial Results. This is the first randomised trial to show that adding [⁶⁸Ga]Ga-PSMA-11 PET-CT to MRI can safely halve the number of men needing a prostate biopsy. Hot off the press in @TheLancetOncol 🎉 In 660 men across Australian sites with PI-RADS 2-3 but high clinical risk, PSMA-PET: - Avoided biopsy in nearly half (49%) - Was non-inferior for detecting clinically significant cancer (12% vs 16%) - Halved the overdiagnosis of insignificant cancer (32% to 14%) Fewer biopsies, less overdiagnosis, whilst not missing clinically significant prostate cancer: a real step forward for the diagnostic pathway. Enormous congratulations to @ButeauJames @PeterMacCC , who led this as the centrepiece of his PhD and presented it as a plenary at #EAU26 in London. And to my brilliant co-lead @drlouiseemmett - this was a true partnership across our two centres. Thank you to the UROLOGISTS @DrDanielMoon @declangmurphy (& many others), nuclear medicine physicians, technologists, radiopharmaceutical scientists across every site, and to @AnnetteVDHeyden and the @pros_tic who held it all together. We are grateful to our funders: @PCF_Science, @nhmrc, St Vincent's Curran Foundation, Peter MacCallum Cancer Foundation, and @ANZUPtrials Most of all, thank you to the 660 men who took part. Open Access article: thelancet.com/journals/lanon…

Thank you so much for the invitation, the excellent organisation, and a great time in Madrid. Always nice to catch up with friends and colleagues and discuss how we can do better. ¡Gracias por todo!

🚨 STAMPEDE: AI biomarker may help select who needs abi intensification in VHR localized #prostatecancer Just out in @Annals_Oncology 🧬 >1k pts w/ non-metastatic very high-risk PCa from 2 randomized STAMPEDE phase 3 abi trials. 🤖 Multimodal AI using routine H&E PSA/stage/age 📉 MMAI very high-risk: abi LT-ADT markedly improved MFS: HR 0.47. 5-yr MFS 81% vs 62%. 🎯 MMAI standard high-risk: benefit was limited: HR 0.83. 5-yr MFS 84% vs 82%. Interaction P=0.02. 🧠 Signal in both node-negative & node-positive pts ⚖️ Implication: intensify where benefit is ⬆️, spare overtreatment/toxicity where benefit is ⬇️. 🔗shorturl.at/FoHKo @PCFnews @PCF_Science @urotoday @UrologyTimes

Dear Colleagues in #Prostate Cancer Introducing #APCCC26 Live from Lugano🇨🇭Series By @APCCC_Lugano RT ADT ± ARPI in high-risk localized prostate cancer—where do we stand? Drs. Bertrand Tombal, Christopher Sweeney, and Jeff Michalski discuss patient selection, biomarkers, reimbursement challenges, pelvic nodal RT, and the evidence shaping treatment intensification. in this video: 👇 How should ARPIs be integrated into practice? Series Faculty @BertrandTOMBAL @ChrisSweens1 @jmmrad @drjefstathiou @CaPsurvivorship @LoebStacy @charlesryanmd @AarmstrongDuke @Ecastromarcos @LVM_Walz @piet_ost @Nicola_Fossati @AnthonyMJoshua @Prof_Nick_James @VedangMurthy @AttardLab @Silke_Gillessen @AOmlin Pinging @AmandaNizamMD @scocmem @nataliagandur @gu_onc @tompowles1 @brian_rini @declangmurphy @cdanicas @neerajaiims

Great experience at Masterclass in BCa. Thanks to @DrFelixGuerrero and @cdanicas for this fantastic course.

Muchísimas gracias @DrFelixGuerrero y @cdanicas por invitarme a la III Masterclass en cáncer de vejiga celebrado en el Hospital 12 octubre Un placer haber moderado la sesión junto con @DrFelixGuerrero @RodriguezFaba @evanguelosx José Luis Domínguez Excelente organización

🎉 ¡Hito para @Blatam_urology ! 🎉 🏥 Hoy celebramos la inclusión del 1° paciente enrolado en el estudio BLATAM #NMIBC. 🔬 Cada paciente🧍cuenta. Cada dato suma. Cada estudio acerca nuevas oportunidades para nuestros pacientes #InvestigaciónClínica #CáncerVejiga #PrimerPaciente

Wonderful stay in Madrid at @H12Octubre with the amazing Prof. Dani Castellano @cdanicas and Dr. Felix Guerrero @DrFelixGuerrero for the outstanding #Masterclass in Bladder Cancer 2026: a lot of science and discussions over the entire disease spectrum! @giannatempopatr @drenriquegrande

Back from an outstanding #Masterclass in Madrid. It was a privilege to discuss emerging and future targets in urothelial cancer with @cdanicas, @DrFelixGuerrero and @GuglielmoVelasco. As always, @drenriquegrande and @nachoduranm provided truly inspiring perspectives. @oncodaily

Dear Colleagues at #ASCO26 Thank you for joining us and reminding you that THE COMPLETE ONCOALERT NEWSLETTER with ALL of our picks from #ASCO26 comes out this Thursday and conveniently to your Inbox REGISTER HERE 👉buff.ly/bTpzTQY @DrChoueiri 🇺🇸 @hoperugo 🇺🇸 @matteolambe 🇮🇹 @TiansterZhang 🇺🇸 @CathyEngMD 🇺🇸 @stolaney1 🇺🇸 @montypal 🇺🇸 @tompowles1 🇬🇧 @brian_rini 🇺🇸 @cdanicas 🇪🇸 @NiuSanford 🇺🇸 @amerseburger 🇩🇪 @GlopesMd 🇺🇸 @Icro_Meattini 🇮🇹 @PGrivasMDPhD 🇺🇸 @DrYukselUrun 🇹🇷 @nataliagandur 🇦🇷 @ElisaAgostinett 🇧🇪 @HHorinouchi 🇯🇵 @realbowtiedoc 🇺🇸 @to_be_elizabeth 🇮🇹 @UOzkerim 🇹🇷 @p_ciracimd 🇮🇹 @DrVilmaPBarcia 🇪🇸 @DraMartinezLago 🇪🇸 @DrMirallas 🇺🇸 @GaiaGriguolo 🇮🇹 @MarioBalsaMD 🇪🇸 @scocmem 🇬🇧 @AmandaNizamMD 🇺🇸 & @weoncologists 🇺🇸

Thank you for the invitation. It will be a very interesting day with valuable discussions on bladder cancer. Looking forward to it.” @FPuigvert @actasurologicas

📍 Arranca en Madrid la III MasterClass in Bladder Cancer Desde TACTICS acompañamos esta jornada presencial de actualización científica centrada en los principales avances y retos en el manejo del cáncer de vejiga. La MasterClass cuenta con la coordinación del Dr. @cdanicas y el Dr. @DrFelixGuerrero, reuniendo a especialistas para compartir conocimiento, experiencia clínica y nuevas perspectivas terapéuticas. Inauguran el encuentro con los Dres. @PazAresLab y @arguezantolin Empezamos #BladderMasterClass26